OV-329 is a small molecule commercialized by Ovid Therapeutics, with a leading Phase I program in Seizures. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of OV-329’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for OV-329 is expected to reach an annual total of $98 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
OV-329 Overview
Small molecule is under development for the treatment of resistant orphan epilepsy associated with tuberous sclerosis complex, focal seizures (partial seizure), status epilepticus, infantile spasms, drug addiction, acute and chronic seizures. The drug candidate is administered through oral and intravenous route. It acts by targeting GABA aminotransferase.
Ovid Therapeutics Overview
Ovid Therapeutics is a biopharmaceutical company that includes drug discovery and development for epilepsies and rare CNS disorders. The company’s product pipeline such as soticlestat, GV101, OV329 and OV350. Its pipeline treats dravet syndrome and lennox-gastaut syndrome (LGS), cerebral cavernous malformations, tuberous sclerosis complex, infantile spasms, resistant epilepsies and neuropathologies. Ovid Therapeutics carries out drug discovery and development. The company works in partnership with patients, clinicians and scientists, foundations, academic centers, regulatory agencies and Graviton Biosciences. Ovid Therapeutics is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$1.5 million for the fiscal year ended December 2022 (FY2022), a decrease of 99.3% over FY2021. The operating loss of the company was US$55.6 million in FY2022, compared to an operating profit of US$124.2 million in FY2021. The net loss of the company was US$54.2 million in FY2022, compared to a net profit of US$122.8 million in FY2021.
The company reported revenues of US$0.1 million for the second quarter ended June 2023, an increase of 13.4% over the previous quarter.
For a complete picture of OV-329’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.